Search clinical trials for: UCB7665

Total 18 results

UCB Biopharma SRL

Completed

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Serbia, Spain, Taiwan, United Kingdom
UCB Celltech
Parexel

Completed

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

Healthy

United Kingdom
UCB Biopharma SRL

Not yet recruiting

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis (roMyG)

Generalized Myasthenia Gravis
UCB Biopharma SRL
Parexel

Completed

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Thrombocytopenia

Australia, Bulgaria, Czechia, Georgia, Germany, Italy, Moldova, Republic of, Poland, Romania, Spain, United Kingdom
UCB Biopharma SRL

Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy2)

Primary Immune Thrombocytopenia

United States, Bulgaria, China, France, Germany, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
UCB Biopharma S.P.R.L.

Completed

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, Germany, Spain
University of Southern Denmark

Completed

Does the Natural Medicinal Plant St John's Wort Affect the Glucose Tolerance in Healthy Individuals

Type 2 Diabetes

Denmark
UCB Biopharma SRL

Completed

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom
UCB Biopharma SRL

Recruiting

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD) (cosMOG)

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)

United States, Australia, Belgium, Czechia, France, Germany, Italy, Japan, Korea, Republic of, Mexico, Spain, Sweden, Switzerland, Turkey, Portugal, United Kingdom, Brazil, Ukraine, Taiwan
UCB Biopharma SRL

Completed

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Canada, Czechia, Denmark, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Serbia, Spain, Taiwan
UCB Biopharma SRL

Terminated

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy3)

Primary Immune Thrombocytopenia

United States, China, Georgia, Germany, Hungary, Italy, Japan, Moldova, Republic of, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
UCB Biopharma SRL

Active, not recruiting

A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

Fibromyalgia

United Kingdom
UCB Biopharma SRL

Completed

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Canada, Czechia, Denmark, France, Germany, Italy, Japan, Poland, Russian Federation, Spain, Taiwan
UCB Biopharma SRL

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy1)

Primary Immune Thrombocytopenia

United States, Bulgaria, France, Georgia, Greece, Hungary, Italy, Japan, Korea, Republic of, Moldova, Republic of, Poland, Romania, Russian Federation, Taiwan, Ukraine, United Kingdom
Tehran University of Medical Sciences

Completed

Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Major Depressive Disorder

Iran, Islamic Republic of
UCB Biopharma SRL

No longer available

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
UCB Biopharma S.P.R.L.

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (MyCIDPchoice)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

Healthy-volunteers

United Kingdom

Search clinical trials for: UCB7665

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations